[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-otitis-media-aom\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-otitis-media-aom":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,70,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100609580","phase-2-safety-and-efficacy-of-wsp-vaccine-in-young-children-100609580",false,"NCT07216430","Safety and Efficacy of wSp Vaccine in Young Children","A Phase 2 Study Evaluating the Safety and Efficacy of Whole-Cell Pneumococcal Vaccine (wSp) in Reducing Nasopharyngeal Colonization by Streptococcus Pneumoniae in Young Children.","wSp005","Inclusion Criteria:\n\n1. Male or female who is 6 months (- 30 to +75 days) of age at time of enrollment\n2. Healthy subject as established by medical history and clinical examination before entering into the study.\n3. Received 3 doses of PCV15 or PCV20.\n4. Written informed consent obtained from the subject's parent\u002Flegal guardian.\n5. Parent\u002Flegal guardian able and willing to bring subject to all study visits.\n\nExclusion Criteria:\n\n1. Has a history of invasive pneumococcal disease (positive blood culture and\u002For positive cerebrospinal fluid culture).\n2. Known or suspected impairment of immunological function, based on medical history and physical examination.\n3. Has a history of congenital or acquired immunodeficiency.\n4. Chronic administration (defined \\> 14 consecutive days) of immunosuppressants or other immune-modifying drugs.\n5. Prior receipt since birth of immunoglobulins and\u002For any blood products or planned administration during the study period.\n6. Expected to receive systemic corticosteroids within 14 days prior to any dose of study vaccine.\n7. External auditory canal atresia\u002Fstenosis.\n8. Has known or history of functional or anatomic asplenia.\n9. Has a bleeding disorder in which intramuscular vaccination would be contraindicated.\n10. Participation in another investigational or interventional trial within the 28-day period before enrollment and during the conduct of the study. Participation in observational studies is permitted.\n11. Direct descendant (child or grandchild) of study site personnel.\n\n    Temporary exclusion criteria\n\n    For day of vaccination:\n12. Fever (transcutaneous temperature ≥38.0°C) or acute illness, at investigator's discretion\n13. Has received systemic corticosteroids (equivalent of prednisone \\> 0.5 mg\u002Fkg\u002Fday or equivalent) and not completed this course of treatment at least 30 days prior to the study vaccination. Inhaled, topical, and ophthalmic steroids are allowed.",true,"ALL","5 Months","7 Months",{"count":22,"type":23},320,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The goal of this clinical trial is to evaluate whether the wSp vaccine can prevent nasopharyngeal colonization by pneumococcal bacteria in healthy young children who have received routine PCV15 or PCV20 vaccination.\n\nThe main questions it aims to answer are:\n\nDoes wSp vaccine reduce pneumococcal colonization in the nose? Does wSp vaccine safely stimulate the immune system to produce antibodies and protective immune responses?\n\nResearchers will compare children receiving two injections of wSp vaccine to those receiving saline placebo to see if wSp vaccine reduces colonization and boosts immunity.\n\nParticipants will:\n\nReceive two injections of either wSp or saline at approximately 7 and 9 months of age.\n\nHave blood samples taken at 6 and\u002For 12 months to measure immune responses. Have nasal swabs collected at several time points and during infections from 6-24 months.\n\nBe monitored for ear infections, respiratory illnesses, and other pneumococcal-related infections.",[29],"Acute Otitis Media (AOM)","RECRUITING","2026-05-29",{"date":33,"type":34},"2026-06-02","ACTUAL",{"date":36,"type":34},"2025-09-29",{"date":38,"type":23},"2029-06",{"name":40,"class":41},"Serum Life Science Europe GmbH","INDUSTRY",7,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":17,"sex":18,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":24,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100631427","evaluation-of-the-medentum-diagnostik-platform-for-pediatric-ent-conditions-and-asthma-100631427","NCT07500532","Evaluation of the Medentum Diagnostik Platform for Pediatric ENT Conditions and Asthma","Inclusion Criteria:\n\n* Age: Patients between the ages of 4 and 17 years (asthma) and 3-17 years (ENT)\n* Diagnosis:\n\n  o Asthma patients: Diagnosed with mild-to-moderate and severe persistent asthma according to Global Initiative for Asthma (GINA) guidelines, with a history of symptoms or exacerbations requiring medical intervention (prior prednisone course and\u002For albuterol for \\>24 hours in context of acute wheezing episode) in the past 12 months. ENT patients: Diagnosed with common ENT conditions such as acute otitis media (AOM) or strep pharyngitis in the prior year. Diagnosis must be based on established clinical guidelines.\n* Technology access: Must have access to a smartphone, tablet, or other device capable of running the Medentum Diagnostik platform app and access to Wifi or cellular service.\n* Care access: Must be receiving routine care from University of Arizona or associated clinics in Arizona and have active health insurance\n* Consent: Must have parental or guardian consent for participation, as well as child assent when appropriate.(all children ≥7 yrs)\n\nExclusion Criteria:\n\n* Other medical conditions: Patients with additional chronic lung diseases (such as cystic fibrosis) requiring complex specialist care will be excluded. cerebral palsy, neurodevelopmental conditions, congenital heart disease. Patients with complex chronic conditions or chronic ENT conditions requiring complex specialist care will be excluded.\n* Recent surgical\u002Fcomplex ENT medical history: Patients who have had tympanostomy tubes or tonsillectomy\u002Fadenoidectomy, patients with chronic ENT conditions including chronic suppurative or serous otitis media\n* Recent medical history: Patients who have experienced severe asthma exacerbations requiring hospitalization or intensive treatment in the past 4 weeks\n* Comorbidities: Patients with speech delays, hearing impairments, or cognitive impairments that may affect their ability to use the Diagnostik platform accurately will be excluded.\n* Non-compliance risk: Patients or families that are unable to follow study instructions, comply with follow-up visits, or properly use the Medentum platform will be excluded.","3 Years","17 Years",{"count":52,"type":23},84,[54],"NA","This study evaluates the diagnostic performance, usability, and clinical utility of the Medentum Diagnostik platform, a multisensor device with integrated software and artificial intelligence, in pediatric patients with asthma and ENT conditions. Participants will be assigned to either home-based use of the Diagnostik platform with telehealth-supported clinician evaluation or standard in-person care.\n\nThe primary objective is to assess agreement between AI-generated diagnoses and clinician diagnoses obtained during study encounters, including telehealth evaluations in the Diagnostik arm and in-person evaluations in the standard-of-care arm. Secondary objectives include evaluating agreement between AI-generated diagnoses and independent research team diagnoses, as well as assessing usability, patient and caregiver satisfaction, healthcare utilization, and clinical outcomes such as asthma control and symptom resolution.\n\nThis study will also evaluate differences in healthcare utilization, including in-person visits, emergency care use, and time to diagnosis and treatment, between study groups.",[29,57,58,59],"Strep Pharyngitis","Asthma Exacerbation","Pediatric Asthma","2026-03-25",{"date":62,"type":34},"2026-03-30",{"date":64,"type":34},"2025-10-01",{"date":66,"type":23},"2026-12-01",{"name":68,"class":41},"Medentum Innovations",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":24,"phases":80,"briefSummary":81,"conditions":82,"keywords":93,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":69},"100620566","impact-of-a-multimodal-intervention-on-antibiotic-prescribing-for-respiratory-infections-in-primary-care-100620566","NCT07359287","Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care","Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care: A Cluster-Randomized Trial","GRASP","Inclusion Criteria:\n\n\\- Patient seen in consultation for an upper or lower respiratory tract infection (Angina, Acute bronchiolitis, Acute bronchitis, COPD exacerbation (AECOPD), Laryngitis, Acute otitis media (AOM), Serous or congestive otitis, Viral respiratory infection (e.g., influenza), Community-acquired pneumonia (CAP), Rhinitis \u002F Nasopharyngitis, Acute sinusitis)\n\nExclusion Criteria:\n\n\\- Patient under legal protection",{"count":79,"type":23},4500,[54],"Antimicrobial resistance (AMR), considered one of the greatest global threats by the WHO, justifies the development of initiatives to promote appropriate antibiotic use-especially in primary care, where most antibiotics in France are prescribed and where misuse remains common.\n\nWe are proposing a cluster-randomized controlled trial to evaluate the effectiveness of a bimodal intervention combining: (1) improved communication about the circulation of respiratory viruses, and (2) strengthened collaborative practices between general practitioners and pharmacists through a multidisciplinary protocol aimed at verifying that prescribed treatment durations comply with guidelines.\n\nThe study will include six primary care practices (24 physicians), with three practices in each study arm.\n\nThe aim of this project is to assess whether the bimodal intervention can reduce the duration of antibiotic treatments for upper and lower respiratory tract infections. The first component (a \"viral infection prescription\" tool) focuses on reducing unnecessary treatment initiation, while the second (pharmacist-led review) aims to shorten excessive prescription durations.",[83,84,85,86,87,29,88,89,90,91,92],"Angina","Acute Bronchiolitis","Acute Bronchitis","COPD Exacerbation (AECOPD)","Laryngitis","Serous or Congestive Otitis","Viral Respiratory Infection (e.g., Influenza)","Community-Acquired Pneumonia (CAP)","Rhinitis \u002F Nasopharyngitis","Acute Sinusitis",[94,95],"Upper respiratory tract infection","Lower respiratory tract infection","2026-01-13",{"date":98,"type":34},"2026-01-22",{"date":100,"type":34},"2025-12-01",{"date":102,"type":23},"2026-09-01",{"name":104,"class":105},"University Hospital, Caen","OTHER",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":18,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":24,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100583433","artificial-intelligence-diagnostic-decision-support-to-reduce-antimicrobial-prescriptions-in-young-children-with-colds-100583433","NCT06876259","Artificial Intelligence Diagnostic Decision Support to Reduce Antimicrobial Prescriptions in Young Children With Colds","Intelligent Medical Assessment for Guiding Ear Infection Treatment","IMAGE","Inclusion Criteria:\n\n* Age 6-24 months\n* Presence of upper respiratory infection\n\nExclusion Criteria:\n\n* No upper respiratory infection\n* Otorrhea\n* Tympanostomy tubes\n* Currently taking antimicrobials","6 Months","24 Months",{"count":117,"type":23},300,[54],"Ear infections are common in young children with cold symptoms, but they can be difficult to diagnose due to small ear canals, child movement, and limited viewing time. In this study, investigators will take photos of the eardrums of children 6-24 months of age with upper respiratory symptoms. The photos will be reviewed by imaging software enhanced with artificial intelligence (AI app) to determine whether the AI app changes how ear infections are diagnosed and treated. The AI app has undergone rigorous study and was found to be highly accurate; but how using this technology affects the diagnosis and treatment by clinicians has not been studied. This research may help improve diagnostic accuracy for ear infections and ensure antibiotics are prescribed only for those children who have definite ear infections.",[29,121],"Upper Respiratory Infection",[123,124,125,126,127],"acute otitis media","diagnosis","artificial intelligence","diagnostic classifier","antimicrobial stewardship","2026-01-06",{"date":130,"type":34},"2026-01-07",{"date":132,"type":34},"2025-12-04",{"date":134,"type":23},"2027-07-01",{"name":136,"class":105},"Timothy Shope",2]